Senti Biosciences, Inc. (NASDAQ:SNTI) Receives $8.50 Average PT from Analysts

Senti Biosciences, Inc. (NASDAQ:SNTI) has earned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $8.75.

Several research firms recently issued reports on SNTI. Wall Street Zen upgraded Senti Biosciences from a “strong sell” rating to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a research note on Tuesday, April 21st. Finally, Chardan Capital upped their price objective on Senti Biosciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, May 15th.

Senti Biosciences Stock Performance

NASDAQ:SNTI opened at $0.88 on Friday. The company has a market cap of $27.42 million, a PE ratio of -0.46 and a beta of 2.09. Senti Biosciences has a 52-week low of $0.77 and a 52-week high of $3.88. The stock has a 50-day simple moving average of $0.95 and a 200 day simple moving average of $1.19.

Senti Biosciences (NASDAQ:SNTI) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.22. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. On average, research analysts predict that Senti Biosciences will post -1.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Senti Biosciences

Several large investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new stake in shares of Senti Biosciences in the 4th quarter valued at approximately $40,000. Virtu Financial LLC acquired a new stake in shares of Senti Biosciences in the 4th quarter valued at approximately $46,000. Citadel Advisors LLC acquired a new stake in shares of Senti Biosciences in the 3rd quarter valued at approximately $117,000. Geode Capital Management LLC boosted its holdings in shares of Senti Biosciences by 395.6% in the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after buying an additional 117,588 shares during the last quarter. Finally, Armistice Capital LLC acquired a new stake in shares of Senti Biosciences in the 2nd quarter valued at approximately $1,883,000. Institutional investors and hedge funds own 25.70% of the company’s stock.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.